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in the period September 2013 to June 2014. Quality was assessed using the criteria 
for pharmacoeconomic evaluations from the in the most recent ISPOR guidelines 
and the Serbian pharmacoeconomic guidelines. The impact of the introduction of 
the new rulebook was assessed by comparing the period following its introduction 
with the number and quality of submissions in the preceding period. Results: 
Between September 2013 and April 2014 there were 268 submissions to the NHIF and 
none were accompanied by the necessary pharmacoeconomic analysis. The new 
rulebook was published in April 2014, making budget impact analysis an obligatory 
part of every submission, and cost-effectiveness analysis obligatory for all new 
INNs. 127 new and renewal submissions were made between April and June 2014, 
47 for new INNs, 31 original and 16 for innovative medicines. All 47 completed the 
obligatory pharmacoeconomic analysis. There was a widespread failure to reach the 
requirements laid out in either the Guidelines for Pharmacoeconomic Evaluations 
for Serbia or ISPOR guidelines. ConClusions: The introduction of compulsory 
pharmacoeconomic component to reimbursement submissions in Serbia has raised 
the standard of submissions to the NHIF. This standard is still too low to fully facili-
tate transparent evidence based decision making, however the new rulebook is 
expected to force both the NHIF and the pharmaceutical industry to increase their 
skills in evidence based decision making. However, Serbia still suffers from a lack 
of the information required to construct quality pharmacoeconomic analysis, with 
limited local cost estimates available and limited supply of health economic skills 
in the region.
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objeCtives: The goal of this study is to assess whether prices of innovative drugs 
in the top 5 EU markets converge over time. Methods: Price trends of a sample of 
50 innovative drugs, approved by the European Medicines Agency (EMA) in 2009 or 
earlier, that are still patent-protected and marketed in each of the top 5 EU markets 
were analysed over the period 2009-2014. The focus was on ex-manufacturing prices, 
which were extracted from IHS’s international pricing database POLI. Discounts and 
rebates were excluded from the analysis, and current exchange rates into Euros 
were used. Given the timeframe, none of the products included in the sample was 
assessed under the AMNOG reform in Germany. Results: While the data indicates 
that there are still price differences across countries in 2014, these differences have 
declined over time. In 2009, the price difference between the highest priced country 
(Germany) and the lowest one (United Kingdom) was 24%; this figure dropped down 
to 15% in 2014. The average price of the 50 products declined in all countries and 
the overall price mean (all countries) slightly decreased - by around 5% - over the 
period studied: from € 303.3 in 2009 to € 289.0 in 2014. This demonstrates a global 
trend leading innovative drug prices to decrease over time while they are still patent 
protected. ConClusions: Our data shows that prices slightly decrease over time, 
and also that prices have started to decline in Germany. German prices in the sample 
are still comparatively higher than the other major European markets, but with 
most prices in Italy and Spain remaining constant, and those in France converging 
to the mean, there are clear trends of price corridors shrinking across Europe. The 
divergence is commonly larger at launch, and converges over time.
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objeCtives: Since 2009, Greece has implemented a fiscal consolidation pro-
gramme that includes several reforms and budget cuts in health sector. Indicatively, 
health expenditure has been reduced by more than 20% between 2009 and 2012. 
Pharmaceutical sector can be characterized as one of the main sources of these 
cuts. The objective of this study is to draw some early conclusions regarding the 
impact of the current pharmaceutical policy on the structure of expenditure and the 
access to medicines. Methods: The data are obtained from the Hellenic Statistical 
Authority, the national accounts and the household surveys for the period 2009-
2012, in order to examine potential changes of the public/private mix of the phar-
maceutical expenditure. Results: Public pharmaceutical expenditure fell from € 5.1 
bn in 2009 to € 3 bn in 2012 (-42.5%). Private pharmaceutical expenditure was € 1.3 bn 
in 2009, while it was approximately € 1.5 bn in 2012 (+12.4%). The total expenditure 
dropped by 31.2%. The share of private expenditure on pharmaceuticals has sharply 
increased during the study period. Specifically, the private expenditure was 20.6% 
of the total pharmaceutical expenditure in 2009, while it approximated 34% in 2012. 
ConClusions: The aforementioned imply that there is a shift from public to pri-
vate spending for pharmaceuticals between 2009 and 2012. Moreover, preliminary 
estimates for 2013 suggest that this trend is increasing. Therefore, apart from the 
existing financial and income constraints, households are in front of an additional 
financial burden. This change is associated with potential catastrophic expenditures 
and reduction in patient compliance. The study findings suggest that individuals’ 
degrees of freedom are constrained and that patients express their preferences by 
increased out of pocket payments. In the light of the above, the pharmaceutical 
policy implemented so far can be associated to a sharp “indirect increase” of copay-
ment and coinsurance rates. 
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Based on ex-factory prices per Standard Unit SU (tablet, vial etc.), price indices were 
calculated. Study results showed international pharmaceutical price levels (in Euro 
and purchasing power parities) and expenditure per capita. Observation period was 
the year 2012. Data were collected via international literature review and based on 
IMS Health data on file. Results: The international comparison of prices indices 
based on SU prices showed (European average price = 100), France (138) and UK (126) 
had the highest price indices and in contrast to Netherlands (69) and Romania (69) 
were at the lower end. In the international country sample, the Netherlands had the 
highest health expenditure (11.91% of GDP) in 2011, closely following by France with 
11.33% of GDP. Subsequently, Switzerland occupied a leading position based on the 
determined price index per capita (187) per ex-factory price, followed by Sweden 
(167). The rear was Romania (45). ConClusions: In case of converting drug prices 
with purchasing power parities differences between drug prices and affordability 
in different countries were found. Low income countries reported less affordability 
of drugs, leaving room for potential problems with drug access, and consequently, 
a negative impact on health.
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objeCtives: Generics are commonly accepted to contribute significantly to treating 
disease by improving the affordability of pharmaceuticals. Once the patent expires 
for an originator brand, generics erode prices through creating fierce competition. 
The objective of this study is to investigate on Turkish pharmaceutical policies over 
generics through measuring how much they lower the prices, and then develop 
alternative strategies to maintain higher level of price reduction and hence sav-
ing. Methods: Claims data from Turkish Social Security Institution for all ambula-
tory care drugs reimbursed were collected monthly in the period of January 2009 to 
December 2013. First, the share of generic drugs both in terms of sales volume and 
value were calculated. Then, selected 12 equivalent groups each relying on same 
molecule were evaluated and saving impacts due to generic entry were computed. 
Finally, the price erosion for 15 generics entering the reimbursement list in 2012 as 
first generics was measured. Results: Only 48% of all units sold was prescribed as 
generic drugs, whereas it was only 31% when it comes to value. For 12 equivalent 
groups constituting nearly 7% of SSI drug spending, the price erosion was nearly 
41% ranging from 8% to 74%. Interestingly, when a first generic having an origina-
tor brand whose any form were marketed before 1987 in any country entered the 
market, new discounted public price was higher than the price with no generic. 
Finally, in the first year of the first generic entry, on average the prices were only 
shrunk by 39% with an increase of 41% in units sold. ConClusions: Turkey is not 
maximizing its full potential with respect to generic medicines. Therefore, it is 
of great importance that policies such as therapeutic equivalence, tendering, and 
aggressive generic pricing policy to stimulate higher savings need to be introduced.
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objeCtives: Targeted therapies (e.g. trastuzumab, cetuximab) are often said to 
constitute a new era of medicine. The new agents promise to be more effective 
and less toxic than standard care. The consequences on costs are still a matter of 
debate. While proponents refer to the enormous cost saving potential due to the 
avoidance of side effects or hospitalizations for example, opponents expect a mas-
sive increase in costs of care. However, the impact of targeted therapies on cost as 
well as their benefits are not yet clear. This review assesses the cost-effectiveness of 
targeted therapies. Methods: We searched Medline, the Cochrane Library, Scopus, 
ISI Web of Knowledge and ScienceDirect for relevant articles published between 2001 
and 2013. Internet search and scanning reference lists complemented our search. 
Authors independently reviewed titles, assessed articles’ eligibility for inclusion, 
determined methodological quality and extracted relevant data. Results: In total 
487 studies were identified. 50 of them met the inclusion criteria. 39 studies tar-
get either trastuzumab, or one of the aromatase inhibitors anastrozole, letrozole 
or exemestane. Quality of the studies was assessed using the checklist provided 
by Drummond/Jefferson (1996). The majority of the studies scored 80% or higher. 
With few exceptions studies are based on Markov models. Effectiveness as well as 
cost data were mostly obtained from clinical trials or literature respectively. Stated 
cost-effectiveness ratios ranged from 4.370€ /QALY to 220.658€ /QALY, whereas the 
majority of studies report favorable incremental cost-effectiveness ratios (≤ 50.000€ /
QALY). Models often did not incorporate the respective companion test adequately. 
Almost all studies were funded by the pharmaceutical industry. Studies without 
financial support report higher cost-effectiveness ratios. ConClusions: Results 
of the review indicate that targeted therapies seem to be cost-effective compared 
to standard care. As most of the studies have been funded by pharmaceutical com-
panies, authors suggest that results must be interpreted with care.
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objeCtives: To assess the impact of new rules for pharmacoeconomic evaluations 
in Serbia, after the publishing of a new rulebook covering the criteria, methods and 
conditions for listing medicines for reimbursement. Methods: We investigated the 
reimbursement submissions to the National Health Insurance Fund (NHIF) in Serbia, 
